Matches in Nanopublications for { ?s ?p "To determine the capacity of EGFR inhibition to block PGE2-dependent cell proliferation, cells were pretreated with Erlotinib or PD153035 prior to PGE2 stimulation. We observed a significant increase of NSCLC cell proliferation in response to PGE2 treatment that was resistant to EGFR inhibition (Fig. 6). Treatment with EGFR inhibitors or sc58236 alone had only a modest effect on cell proliferation. However, treatment with the combination of both drugs significantly decreased proliferation of NSCLC cells compared with either drug alone or nontreated control cells." ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- _4 value "To determine the capacity of EGFR inhibition to block PGE2-dependent cell proliferation, cells were pretreated with Erlotinib or PD153035 prior to PGE2 stimulation. We observed a significant increase of NSCLC cell proliferation in response to PGE2 treatment that was resistant to EGFR inhibition (Fig. 6). Treatment with EGFR inhibitors or sc58236 alone had only a modest effect on cell proliferation. However, treatment with the combination of both drugs significantly decreased proliferation of NSCLC cells compared with either drug alone or nontreated control cells." provenance.
- _4 value "To determine the capacity of EGFR inhibition to block PGE2-dependent cell proliferation, cells were pretreated with Erlotinib or PD153035 prior to PGE2 stimulation. We observed a significant increase of NSCLC cell proliferation in response to PGE2 treatment that was resistant to EGFR inhibition (Fig. 6). Treatment with EGFR inhibitors or sc58236 alone had only a modest effect on cell proliferation. However, treatment with the combination of both drugs significantly decreased proliferation of NSCLC cells compared with either drug alone or nontreated control cells." provenance.
- _2 value "To determine the capacity of EGFR inhibition to block PGE2-dependent cell proliferation, cells were pretreated with Erlotinib or PD153035 prior to PGE2 stimulation. We observed a significant increase of NSCLC cell proliferation in response to PGE2 treatment that was resistant to EGFR inhibition (Fig. 6). Treatment with EGFR inhibitors or sc58236 alone had only a modest effect on cell proliferation. However, treatment with the combination of both drugs significantly decreased proliferation of NSCLC cells compared with either drug alone or nontreated control cells." provenance.
- _2 value "To determine the capacity of EGFR inhibition to block PGE2-dependent cell proliferation, cells were pretreated with Erlotinib or PD153035 prior to PGE2 stimulation. We observed a significant increase of NSCLC cell proliferation in response to PGE2 treatment that was resistant to EGFR inhibition (Fig. 6). Treatment with EGFR inhibitors or sc58236 alone had only a modest effect on cell proliferation. However, treatment with the combination of both drugs significantly decreased proliferation of NSCLC cells compared with either drug alone or nontreated control cells." provenance.